CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Net Income Growth by Quarter and Year

Atara Biotherapeutics,'s Net Income results by quarter and year




ATRA Net Income (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -35.31 -18.24 -21.25
III Quarter September -58.36 -31.10 -25.37 -11.87
II Quarter June -50.88 -27.43 -18.88 -14.95
I Quarter March -41.44 -25.65 -16.56 -9.16
FY   -150.68 -119.49 -79.05 -57.23



ATRA Net Income third quarter 2018 Y/Y Growth Comment
Atara Biotherapeutics, Inc. in the third quarter recorded net loss of $ -58.36 millions.

According to the results reported in the third quarter, Atara Biotherapeutics, Inc. achieved the best Net Income growth in Biotechnology & Drugs industry. While Atara Biotherapeutics, Inc.' s Net Income no change of % ranks overall at the positon no. in the third quarter.




ATRA Net Income ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Atara Biotherapeutics,'s third quarter 2018 Net Income $ 0.00 millions ATRA's Income Statement
Atara Biotherapeutics,'s third quarter 2017 Net Income $ 0.00 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Net Income Growth >>


ATRA Net Income (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Atara Biotherapeutics,'s Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Net Income Comment
III. Quarter 2018 accomplishment of -58.36 millions by Atara Biotherapeutics, Inc. look even less good compare to the net loss -50.88 millions a quarter before.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Net Income growth. While Atara Biotherapeutics,'s Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Net Income Comment
Current accomplishment of -58.36 millions by Atara Biotherapeutics, Inc. look even more unfavourable if you take a look at net loss -50.88 millions in the second quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Net Income growth. While Atara Biotherapeutics,'s Net Income growth quarter on quarter, overall rank is .


Atara Biotherapeutics,'s 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Net Income 12 Months Ending $ -186.00 $ -158.74 $ -135.28 $ -119.49 $ -102.41
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months net loss of $ -186 millions in the Sep 30 2018 period.
The situation is getting worse as the cumulative net loss is becoming larger from $ -158.74 millions for the period from Jun 30 2018 to Sep 30 2017 and $ -50.88 millions from the TTM period ending Sep 30 2017 Cameron Miller mentioned.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months net loss of $ -186 millions in the Sep 30 2018 period.
The business is worsening as the cumulative net loss is inflating from $ -158.74 millions for the period from Jun 30 2018 to Sep 30 2017 and $ -50.88 millions from the TTM period ending Sep 30 2017 Cameron Miller mentioned.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Drugs Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
ATRA's Net Income Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for ATRA's Competitors
Net Income Growth for Atara Biotherapeutics,'s Suppliers
Net Income Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2018
Jazz Pharmaceuticals Plc  135.05 %$ 135.047 millions
Inogen Inc  123.93 %$ 123.930 millions
Bristol Myers Squibb Co  123.36 %$ 123.364 millions
Baxter International Inc  116.73 %$ 116.733 millions
Amedisys Inc  115.18 %$ 115.183 millions
Pro Dex Inc  114.81 %$ 114.809 millions
Innoviva, Inc.  111.08 %$ 111.078 millions
Intricon Corp  107.52 %$ 107.525 millions
Lilly Eli & Co  106.89 %$ 106.893 millions
Abiomed Inc  104.57 %$ 104.575 millions
Mylan N.v.  100.11 %$ 100.113 millions
Medpace Holdings, Inc.  96.37 %$ 96.369 millions
Lhc Group, Inc  93.80 %$ 93.801 millions
National Healthcare Corp  88.55 %$ 88.546 millions
China Senior Living Industry International Holding  87.80 %$ 87.795 millions
Utah Medical Products Inc  86.69 %$ 86.692 millions
Biospecifics Technologies Corp  85.76 %$ 85.759 millions
Spring Pharmaceutical Group, Inc.  82.42 %$ 82.417 millions
U S Physical Therapy Inc  80.15 %$ 80.149 millions
Supernus Pharmaceuticals Inc  75.50 %$ 75.497 millions
Laboratory Corp Of America Holdings  73.94 %$ 73.937 millions
Hca Healthcare, Inc.  69.06 %$ 69.057 millions
Abbvie Inc.  68.42 %$ 68.424 millions
Techcare Corp.  66.40 %$ 66.399 millions
Zimmer Biomet Holdings, Inc.  64.07 %$ 64.069 millions
Icu Medical Inc  61.03 %$ 61.029 millions
Dynatronics Corp  58.88 %$ 58.875 millions
Exelixis, Inc.  55.60 %$ 55.600 millions
Cambrex Corp  54.54 %$ 54.539 millions
Regeneron Pharmaceuticals Inc  53.14 %$ 53.136 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HMMR's Profile

Stock Price

HMMR's Financials

Business Description

Fundamentals

Charts & Quotes

HMMR's News

Suppliers

HMMR's Competitors

Customers & Markets

Economic Indicators

HMMR's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071